KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arbutus Biopharma (ABUS) Long-Term Investments (2016 - 2024)

Historic Long-Term Investments for Arbutus Biopharma (ABUS) over the last 13 years, with Q3 2024 value amounting to $3.0 million.

  • Arbutus Biopharma's Long-Term Investments fell 7176.07% to $3.0 million in Q3 2024 from the same period last year, while for Sep 2024 it was $3.0 million, marking a year-over-year decrease of 7176.07%. This contributed to the annual value of $6.3 million for FY2023, which is 8318.12% down from last year.
  • Arbutus Biopharma's Long-Term Investments amounted to $3.0 million in Q3 2024, which was down 7176.07% from $6.5 million recorded in Q2 2024.
  • In the past 5 years, Arbutus Biopharma's Long-Term Investments registered a high of $56.3 million during Q1 2022, and its lowest value of $1.6 million during Q2 2020.
  • For the 5-year period, Arbutus Biopharma's Long-Term Investments averaged around $23.2 million, with its median value being $11.1 million (2023).
  • In the last 5 years, Arbutus Biopharma's Long-Term Investments crashed by 8887.11% in 2020 and then soared by 8155.5% in 2022.
  • Quarter analysis of 5 years shows Arbutus Biopharma's Long-Term Investments stood at $1.6 million in 2020, then surged by 2130.5% to $35.7 million in 2021, then increased by 4.69% to $37.4 million in 2022, then crashed by 83.18% to $6.3 million in 2023, then crashed by 52.83% to $3.0 million in 2024.
  • Its Long-Term Investments was $3.0 million in Q3 2024, compared to $6.5 million in Q2 2024 and $8.7 million in Q1 2024.